RPHM Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.

$6.87  +0.80 (13.18%)
As of 12/06/2021 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/09/2021
Outstanding shares:  24,423,900
Average volume:  39,353
Market cap:   $148,253,073
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75974E103
ISIN:        US75974E1038
Sedol:      BMHR7T5
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.07
PS ratio:   0.00
Return on equity:   -22.67%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy